#StayInformed: May 2024 PubMed curation

  • Carmanius et al, JEADV 2024
    ➜ DOI: 10.1111/jdv.20076
    A cross-sectional study based on the 24-year follow-up from the population-based birth cohort linked with dispensing data from the National Swedish Drug Register confirms that a large proportion of young adults with AD is undertreated or untreated.
  • Kook et al, JEADV 2024
    ➜ DOI: 10.1111/jdv.20053
    Misdiagnosis of AD or confounding skin diseases in particular cutaneous T-cell lymphoma (CTCL) may lead to inadequate response to dupilumab. This Korean series shows that 12.3% of patients treated with dupilumab showed insufficient response and that around 50% of them were finally diagnosed with mycosis fungoides.
  • Traks et al Exp Dermatol 2024
    ➜ DOI: 10.1111/exd.15079
    This Estonian study used a straightforward methodology with proteomic analysis on full thickness skin samples from adult PS patients, AD patients and healthy subjects. They found that periostin, which is also a biomarker for asthma, is overexpressed in the skin of AD.
  • Mailepessov et al, Sci Rep 2024
    ➜ DOI: 10.1038/s41598-024-60712-4
    This time-series study examines the association between air pollution and meteorological factors with the incidence of outpatient visits for AD obtained from the National Skin Centre (NSC) in Singapore. The authors found a close association between outpatient visits for AD with ambient particulate matter concentrations and rainfall and suggest that seasonal variations in particulate matter and rainfall may be used to alert healthcare providers on the anticipated rise in AD cases and to time preventive measures to reduce the associated health burden.
  • Clawry et al, JCI insight 2024
    ➜ DOI: 10.1172/jci.insight.178789
    The authors identify a systemic and cutaneous immunological signature associated with S. aureus skin infection in a pediatric AD cohort, highly associated with elevated cutaneous chemokines IP10 and TARC, which preferentially direct Th1 and Th2 cells to skin. Systemic CD4+ and CD8+ T cells, except for Th2 cells, were suppressed, particularly circulating Th1, memory IL-10+ T cells, and skin-homing memory Th17 cells. Systemic γδ T cell expansionwas also observed. This study suggests that augmentation of protective T cell subsets is a potential therapeutic strategy in the management of S. aureus in AD.